Potassium nitrate powder
Potassium nitrate is an inorganic salt with a chemical formula of KNO3.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Potassium nitrate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Potassium nitrate
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Chronic heart failure in adults: diagnosis and management (NG106)
Chronic heart failure in adults (QS9)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 20 · 1974–2026
Showing the 50 most relevant studies, sorted by most relevant.
A. Pradeep, Anuj Sharma
Journal of periodontology, 2010
Natalia Raddatz, Laura Morales de los Ríos, M. Lindahl, et al.
Frontiers in Plant Science, 2020
Costacurta AO, Kunz P, Silva RC, et al.
2020
- Dentin Sensitivity
- Nitrates
- Peroxides
Xinxiang Xu, Xin Du, Fen Wang, et al.
Frontiers in Plant Science, 2020
G. Orsini, M. Procaccini, L. Manzoli, et al.
Journal of clinical periodontology, 2010
Zamani P, Shah SJ, Cohen JB, et al.
2025
- Nitrates
- Potassium Compounds
- Stroke Volume
Jiuxin Guo, Yamin Jia, Huanhuan Chen, et al.
Scientific Reports, 2019
Li J, Han Q, Zhang L, et al.
2023
ObjectiveThe purpose of this randomized controlled trial was to compare the efficacy of a toothpaste containing paeonol, potassium nitrate, and strontium chloride with control toothpaste on dentine hypersensitivity (DH).MethodsDH patients who had at least two sensitive teeth and did not use desensitization toothpaste in the past 3 months were randomly allocated to either test or control group. The toothpaste containing paeonol, potassium nitrate, and strontium chloride was used in the test group, while the placebo toothpaste used in control group. The outcome measures included Yeaple probe score and Schiff Index score at 4 and 8 weeks. The patients, personnel and assessors were blinded to the allocation. The differences in Yeaple probe score and Schiff Index score between groups were analyzed with ANOVA.Results91 eligible subjects were randomized. 88 of them completed 8-week follow-up and were analyzed (45 in the test group and 43 in the control group). In both groups, the Yeaple probe score showed an upward trend, while the Schiff sensitivity score showed a downward trend. At week 8, the Yeaple probe score had increased by 30.22 g in the test group, and the Schiff Index score had decreased by 0.89. Compared with the control group, the Yeaple probe score in the test group increased by 286.85% from baseline, and the Schiff Index score decreased by 42.96%, showing a statistically significant difference. Five cases of adverse events were observed.ConclusionThe toothpaste containing paeonol, potassium nitrate, and strontium chloride was effective against DH.Clinical significanceThis combination of paeonol, potassium nitrate and strontium chloride could be a novel functional ingredient choice for anti-hypersensitivity products in future.RegistrationThe trial was registered in the Chinese Clinical Trial Registry (ChiCTR2000041417).
Abstract licence: CC BY-NC-ND
Somacal DC, do Rio MC, Bittencourt HR, et al.
2025
Colognese MRV, Kayser LA, Dalagustinho SKS, et al.
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Potassium (K+) is the principal cation modulating the osmotic balance of the body fluids.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Volume of distribution
Metabolism
6 months
[L1754]
…
Elimination
[L1754]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
In addition, potassium nitrate is used as a diuretic in pigs, cattle, and horses. It is administered orally doses up to 30 g per animal per day [L1736].
[L1751][L1754][L1757]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 874 interactions
[L1736]
The primary acute toxic effect of nitrates is the development of methemoglobinemia, a condition in which greater than 10% of the hemoglobin in the body is transformed into methemoglobin. When this conversion exceeds 70% the condition may result in death .
[L1750]
The potassium ion by itself possesses very little toxicity; the toxicity of the salts is associated with the anion. Potassium nitrate is rapidly absorbed from the upper gastrointestinal tract and is excreted mostly as the unchanged drug .
[L1736]
This excludes a small percentage of the ingested dose that is reduced by the microbial action of the gut to nitrite.
Nitrites convert the hemoglobin in red blood cells into methemoglobin .
[L1736]
In male rats given potassium nitrate, intestinal absorption was affected .
[A32165]
Adverse increased potassium intake included changes in blood lipids, triglyceride, decreased high-density lipoprotein HDL cholesterol), changes in renal function, and increases in catecholamine levels. The decrease in blood volume caused by increased potassium activates the sympathetic nervous system, resulting in the release of adrenaline and noradrenaline. Decreases in blood volume may also contribute to the observed changes in blood lipid concentrations .
[L1755]
Death and severe effects of nitrate ingestion are generally associated with doses of the drugs above 10g NO3-.
Doses ranging from 2-9 g NO3- have been reported to cause methemoglobinemia. These values correspond to 33 - 150 mg NO3-/kg [L1750]
Potassium nitrate was shown to cause low to moderate acute toxicity. Repeated dose toxicity was investigated in rats given oral doses in the range 10-100 mg/kg per day for 4 months; bronchopneumonia, local hemorrhages, and other circulatory disorders were observed in treated animals. Cattle were given oral doses of 345-450 mg/kg daily (expressed as nitrate) for several months; blood phosphate and magnesium were decreased and blood calcium, urinary magnesium, urea and milk urea were increased .
[L1736]
Potassium is the primary agent for common, over the counter de-sensitizing toothpaste that prevents the transmission of nerve endings to the teeth. Potassium salts, including potassium nitrate, potassium chloride or potassium citrate work by diffusion across the dentinal tubules, causing depolarization of the nerve cells. In turn, these cells become unresponsive to excitatory stimuli. The effect of the potassium nitrate accumulates over time, and it may take several weeks for patients to notice improvement of pain symptoms [L1751].
Potassium nitrates control pests using a unique mechanism of action. Rather than directly poisoning rodents, nitrates support the combustion of charcoal in gas cartridges, promoting the production of toxic gases, which, are lethal to the target pest. The environmental protection agency in the USA (EPA) is only minimally concerned about the risk of direct human exposure to sodium or potassium nitrates, rather than pesticide accidents--typically involving skin burns or inhalation of toxic gases [L1759].
Potassium nitrates are ignitable fumigants also utilized as rodenticides and insecticides. They are added to other pesticide active ingredients (sulfur and carbon) and placed into fumigant gas cartridges, designed to be ignited and placed in pest-infested areas. The activated cartridge bombs release toxic gases which are lethal to select rodents, skunks, coyotes, and wasps [L1752].
Potassium ions have demonstrated in animal studies to act directly on the nerves and to reduce sensory activity [L1751]. Tooth hypersensitivity can be relieved by inactivating the intra-dental nerve and inhibiting neural transmission, using suitable medications [L1751].
It has been found that potassium-to-sodium intake ratios are strongly related to cardiovascular disease risk than either nutrient alone. The data describing this relationship warrants further research for various target tissue endpoints [A32167].
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L1754]
The vast majority of intestinal K+ absorption occurs in the small intestine; the contribution of the normal colon to net K+ absorption and secretion is trivial .
[A32174]
[L1754]
[L1754]
The in vivo reduction of nitrates to nitrites depends on conditions that are subject to much variations such the volume and species of microflora present in the saliva/gastrointestinal tract, and stomach pH. Gastric pH is higher in infants younger than 6 months of age and during certain gastrointestinal tract infections, thereby favoring the reduction of nitrates .
[L1754]
Nitrate is metabolized to a small extent. The biotransformation of potassium nitrate consists of nitrate reduction, nitrite formation, nitrite reoxidation to nitrate, and formation of methemoglobin or NO, in a dynamic equilibrium .
[L1752], [L1753], [L1754]
[L1754]
Proteins and enzymes this drug interacts with in the body
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245
Channel properties are modulated by cAMP and subunit assembly .
PMID:10837251
Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization .
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245
Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity PMID:10219239 PMID:9230439
Proteins that transport this drug across cell membranes
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Potassium nitrate
Additional database identifiers
Drugs Product Database (DPD)
7157
ChemSpider
22843
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6251
GenAtlas
KCNH2
GeneCards
KCNH2
GenBank Gene Database
U04270
GenBank Protein Database
487738
Guide to Pharmacology
572
UniProt Accession
KCNH2_HUMAN
GenBank Gene Database
U68759
UniProt Accession
P71278_ENTCL
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7508
GenAtlas
MUC1
GeneCards
MUC1
GenBank Gene Database
M21868
UniProt Accession
MUC1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72